Indazole chloride, a synthetic compound that acts on one form of the body’s estrogen receptors, is able to remyelinate damaged axons as well as alter the body’s immune system, researchers from University of California – Riverside report. The findings could help improve treatment for multiple sclerosis.
Drugs available to treat multiple sclerosis, a leading cause of neurological disability affecting roughly 2.3 million people worldwide, alter the body’s immune system to reduce disease symptoms and disability.
They do not induce, however, repair of damaged axons, the long threadlike parts of nerve cells that conduct impulses between cells or restore myelin, the protective sheath that surrounds the axons of neurons essential for the proper functioning of the brain and spinal cord.
“While additional translational studies are required, indazole chloride and similar drugs may represent a promising new avenue of treating the underlying loss of myelin in multiple sclerosis,”
said Seema Tiwari-Woodruff, an associate professor of biomedical sciences in the School of Medicine, who led the mouse study.
Multiple sclerosis is triggered when the immune system attacks and damages the myelin sheath. As myelin is lost, nerve signals slow down or stop, affecting the patient’s vision, movement, memory, and more.
Oligodendrocytes are the mylenating cells of the central nervous system. Normally, oligodendrocyte precursor cells mature into myelin-producing oligodendrocytes when myelin is damaged.
This process often fails, however, in multiple sclerosis, resulting in permanent damage. The UCR researchers found the change in the immune system provides a protective shield for oligodendrocytes, preventing this damage and possibly even reversing it.
“With remyelination of axons, nerve impulses travel faster than before, thus decreasing multiple sclerosis disability. As a potential therapy for the treatment of multiple sclerosis, indazole chloride may represent the first in a novel class of drugs capable of reducing disability burden in patients with multiple sclerosis. We still don’t know the mechanism of action of pre-clinical therapies like indazole chloride. Our report aims to understand how drugs like indazole chloride are working so we can make more selective and efficacious drugs,”
Indazole chloride, a ligand, stimulates Estrogen receptor β, (ERβ) an estrogen receptor in the body. Indazole chloride is an attractive drug because it does not produce the negative side-effects of estrogen therapy.
Because ERβ are present not just in oligodendrocytes but also in microglia, neurons, and T-cells, indazole chloride may have therapeutic benefits not just for multiple sclerosis, but also other autoimmune diseases.
Tiwari-Woodruff explained that while inflammation causes a lot of damage in autoimmune diseases, not all inflammation is harmful. Beneficial inflammation is required to fight infectious disease and speeds up wound healing by clearing dead cells and tissue.
Indazole chloride reduces “bad” inflammation and promotes “good” inflammation, thereby protecting new oligodendrocytes while they remyelinate. Tiwari-Woodruff and her group found that indazole chloride accomplishes this by strengthening the production of a molecule called “CXCL1,” which makes oligodendrocytes resistant to “bad” inflammatory signals.
Searching For Better Analogs
Tiwari-Woodruff’s findings provide a stepping stone toward a way to repair the damage to axons and oligodendrocytes caused by multiple sclerosis.
In collaboration with John Katzenellenbogen, a research professor of chemistry at the University of Illinois at Urbana-Champaign, Tiwari-Woodruff’s group is screening chemically similar analogs of indazole chloride for more efficacious and safe therapy. Provisional patents have been filed for some of these analogs.
“It’s quite possible we may find an analog far superior to indazole chloride,”
“Our results demonstrate that the interplay between CNS- and immune-derived signals is central to the induction and regulation of neuroinflammatory diseases such as MS. The possibility that ERβ ligands modulate the cytokine and chemokine milieu to potentially promote repair/remyelination opens up exciting therapeutic options,”
the authors conclude.
The research was supported by grants from the National Institutes of Health and the National Multiple Sclerosis Society.
Hawra Karim, Sung Hoon Kim, Andrew S. Lapato, Norio Yasui, John A. Katzenellenbogen, Seema K. Tiwari-Woodruff
Increase in chemokine CXCL1 by ERβ ligand treatment is a key mediator in promoting axon myelination
Proceedings of the National Academy of Sciences May 2018, 201721732; DOI: 10.1073/pnas.1721732115
Top Image: Hawra Karim, et al. CC-BY